Oncology Medical News about iodine-refractory thyroid cancer;survival

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

[90Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer
Cancer, 03/16/09

Iten F et al – Data show that response to [90Y-DOTA]- Tyr3-octreotide (TOC) in metastasized iodine-refractory thyroid cancer was associated with longer survival.

Methods

Aim was to explore the efficacy of 90Yttrium-1,4,7,10-tetra-azacyclododecane N,N,N,N-tetraacetic acid [90Y-DOTA]- TOC in advanced iodine-refractory thyroid cancer
Biochemical response, survival, and the long-term safety profile of systemic [90Y-DOTA]-TOC treatment was estimated
AEs were assessed according to the NCI criteria

Results

24 pts; a median cumulative activity of 13.0 GBq was administered
Response was found in 29.2% pts
33.3% pts developed hematologic toxicity grade 1-3, and 16.7% pts developed renal toxicity grade 1-4
Median survival was 33.4 mo from time of diagnosis and 16.8 mo from time of first treatment
Response to treatment was associated with longer survival from time of diagnosis and from time of first therapy
The visual grade of scintigraphic tumor uptake was not associated with treatment response

<< Previous
Postoperative reduced dose of cisplatin concomitant with...

Next >>
Curcumin sensitizes lung cancer cells to cisplatin-induced...